Key result
A 43-year-old man developed delayed anthracycline-induced cardiomyopathy 26 years after initial chemotherapy, with his ejection fraction dropping to 36% before improving to 64% with heart failure therapy.
Case Report (n=1)
Cardioprotective treatment with ACE inhibitors and beta-blockers can effectively improve left ventricular ejection fraction in patients with delayed anthracycline-induced cardiomyopathy.
Answers are grounded in this paper and cite their sources.
May support reversibility of delayed anthracycline cardiomyopathy with HF therapy; hypothesis-generating and should not yet change practice.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Wiater et al. (2014) conducted a case report in Delayed anthracycline-induced cardiomyopathy (n=1). Anthracycline chemotherapy was evaluated on Left ventricular ejection fraction. A 43-year-old man developed delayed anthracycline-induced cardiomyopathy 26 years after initial chemotherapy, with his ejection fraction dropping to 36% before improving to 64% with heart failure therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: